Gallagher Represents Device Community at National Fly In
Thursday, February 27, 2014
Virginia Bio CEO Jeff Gallagher just returned from two days in Washington DC participating in the annual national policy fly in for AdvaMed, the Advanced Medical Technology Association. Virginia Bio is a member of AdvaMed’s State Medical Technology Alliance. State representatives from across the country were briefed on federal tax and regulatory issues impacting economic growth, innovation and global competitiveness, met with their state’s governor’s office Washington DC representatives, and members and staff in both House and Senate of their state delegations.
Among the issues brought to the attention of lawmakers were protection of FDA user fees, and repeal of the Medical Device excise tax.
Protecting FDA User Fees
Last month the Omnibus Appropriates legislation went into law and retroactively restored sequestered user fees collected by FDA. If the underlying budget agreement is adhered to, there will not be sequestration cuts for FY 14 or FY 15. However, to assure that in the future FDA receives and is able to use 100% of the industry paid user fees, H.R. 2925 and S. 1413 have been introduced.
Medical Device Tax
AdvaMed has worked incessantly for repeal of the Medical Device excise tax since its passage. A House Bill now has 270 co-sponsors including 47 Democrats, and a nonbinding Senate resolution was backed by 79 Senators AdvaMed announced the publication of a new report on the real world impact of the tax based on a survey of its membership. The report details the harm the tax has done to economic growth through jobs lost, to innovation through decreased R&D, and to America’s global competitiveness in the industry. http://advamed.org/res/417/impact-of-the-medical-device-excise-tax
Reforms to the US Patent System, and anti-patent troll legislation
Earlier this month, Jeff Gallagher visited staff of Senator Mark Warner and Senator Tim Kaine with members of the BIO legislative team for informational meetings on the anti patent troll legislation before the Senate. Jeff recounted the successful compromise worked out at the state level in the General Assembly, and explained the underlying concerns of the bioscience innovation industry. Legislators must be careful in crafting changes to the US Patent System in order to stop egregious behavior of a small set of trolls largely in the electronics and IT industry, not to create excessive barriers to enforcing patent rights that will undercut this pillar of bioscience commercialization.,